DOCSLIB.ORG

Genetic and Chemical Modulators of JAK/STAT Signalling in Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic and Chemical Modulators of JAK/STAT Signalling in Cancer Genetic and Chemical Modulators of JAK/STAT Signalling in Cancer Sally Jane Thomas Submitted to the University of Sheffield for the Degree of Doctor of Philosophy September 2015 University of Sheffield, Department of Biomedical Science Abstract ................................................................................................................................. 6 Declaration ............................................................................................................................ 7 Publications ........................................................................................................................... 8 Acknowledgements ............................................................................................................... 9 Abbreviations ..................................................................................................................... 11 List of figures ...................................................................................................................... 13 List of tables ........................................................................................................................ 16 CHAPTER 1: INTRODUCTION ........................................................................... 17 1.1 Overview ....................................................................................................................... 17 1.2 JAK/STAT signalling ................................................................................................... 18 1.2.1 Structure of pathway and pathway components ....................................... 18 1.2.2 JAK/STAT signalling in cancer ................................................................ 27 1.2.3 JAK/STAT signalling in immunity and inflammation ............................. 39 1.2.4 The JAK/STAT pathway as a therapeutic target....................................... 42 1.3 ANKHD1 ....................................................................................................................... 45 1.3.1 ANKHD1 protein ...................................................................................... 45 1.3.2 ANKHD1 gene ........................................................................................... 47 1.3.3 ANKHD1 transcripts ................................................................................. 48 1.3.4 ANKHD1 functions .................................................................................. 49 1.3.5 ANKHD1 in cancer ................................................................................... 54 1.3.6 Rationale behind the investigation of ANKHD1 as a modulator of JAK/STAT signalling. ....................................................................................... 54 1.4 Methotrexate ................................................................................................................. 55 1.4.1 Structure .................................................................................................... 55 1.4.2 Pharmacokinetics ...................................................................................... 55 1.4.3 Methotrexate as a chemotherapy drug ...................................................... 56 1.4.4 Methotrexate in the treatment of inflammatory conditions....................... 57 1.4.5 Rationale behind the investigation of methotrexate as a suppressor of JAK/STAT signalling ........................................................................................ 58 1.5 Synopsis ......................................................................................................................... 59 CHAPTER 2: MATERIALS AND METHODS ................................................... 60 2.1 Cell culture .................................................................................................................... 60 2.1.1 Cell lines and culture conditions ............................................................... 60 2.1.2 Drug and ligand treatments ....................................................................... 63 2.1.3 Transfection of HeLa cells ........................................................................ 64 2.2 Protein techniques ........................................................................................................ 65 2.2.1 Protein extraction ...................................................................................... 65 1 2.2.2 Western Blotting ....................................................................................... 66 2.3 DNA techniques ............................................................................................................ 68 2.3.1 Bacterial culture and starting plasmids ..................................................... 68 2.3.2 Generation of plasmid encoding fragment of ANKHD1 containing first and second ankyrin repeats and the intervening region ..................................... 69 2.4 RNA techniques ............................................................................................................ 73 2.4.1 RNA extraction ......................................................................................... 73 2.4.2 cDNA synthesis ......................................................................................... 73 2.4.3 Quantitative real-time PCR ....................................................................... 73 2.5 Drosophila techniques .................................................................................................. 74 2.5.1 Luciferase assays ....................................................................................... 74 2.5.3 Preparation of fly media containing drugs ................................................ 74 2.5.4 Crosses ...................................................................................................... 74 2.5.5 Tumour assay ............................................................................................ 75 2.6 Kinase profiling ............................................................................................................ 75 2.7 Immunofluorescence .................................................................................................... 75 2.7.1 Preparation of slides .................................................................................. 75 2.7.2 Fluorescence Microscopy.......................................................................... 76 2.7.3 Image analysis ........................................................................................... 76 2.8 Source and initial processing of patient samples ....................................................... 76 2.8.1 Ethical approval ........................................................................................ 76 2.8.2 Whole blood and bone marrow aspirate.................................................... 77 2.8.3 Apheresis material ..................................................................................... 78 2.8.4 Formalin fixed paraffin embedded melanoma samples ............................ 79 2.9 Flow cytometry ............................................................................................................. 79 2.9.1 Development of flow cytometry protocol ................................................. 79 2.9.2 Fixation and permeabilisation ................................................................... 81 2.9.3 Immunostaining ........................................................................................ 82 2.9.4 Assessment of cell viability ...................................................................... 83 2.9.5 Analysis on flow cytometer ...................................................................... 83 2.9.6 Gating strategies ........................................................................................ 84 2.9.7 Flow cytometry calculations ..................................................................... 84 2.10 Immunohistochemistry .............................................................................................. 89 2.10.1 Preparation of slides ................................................................................ 89 2.10.2 Microscopy .............................................................................................. 90 2.11 Antibody validation .................................................................................................... 90 2.12 Statistical analysis .................................................................................................... 925 2 CHAPTER 3: ANKHD1 IN NORMAL BLOOD AND HAEMATOLOGICAL MALIGNANCIES .................................................................................................... 96 3.1 Introduction .................................................................................................................. 96 3.2 Results ........................................................................................................................... 97 3.2.1 Patient characteristics ................................................................................ 97 3.2.2 Quantitative real time PCR ....................................................................... 99 3.2.3 Western Blotting ....................................................................................... 99 3.2.4 ANKHD1 expression in normal blood cells ........................................... 101 3.2.5 ANKHD1 in haematopoietic stem cells .................................................
Load more

Recommended publications
  • Manuscript Submission Manuscript Draft Manuscript Number: BMB-20-087 Title: Emerging Functions for ANKHD1 in Cance
    BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number : BMB-20-087 Title : Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes Article Type : Mini Review Keywords : Ankyrin repeat and KH domain containing 1; ANKHD1; JAK/STAT; YAP1; Cancer Corresponding Author : João Agostinho Machado-Neto Auth ors : Bruna Oliveira de Almeida 1, João Agostinho Machado-Neto 1,* Institution : 1Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil, UNCORRECTED PROOF Mini Review Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes Bruna Oliveira de Almeida, João Agostinho Machado-Neto Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil Running title: ANKHD1, a multitask protein, in cancer cells Key words: Ankyrin repeat and KH domain containing 1; ANKHD1; JAK/STAT; YAP1; Cancer. Corresponding Author: João Agostinho Machado Neto, PhD Department of Pharmacology Institute of Biomedical Sciences of University of São Paulo Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP Phone: 55-11- 3091-7218; Fax: 55-11-3091-7322 E-mail: [email protected] UNCORRECTED PROOF 1 Abstract ANKHD1 (ankyrin repeat and KH domain containing 1) is a large protein characterized by the presence of multiple ankyrin repeats and a K-homology domain. Ankyrin repeat domains consist of widely existing protein motifs in nature, they mediate protein- protein interactions and regulate fundamental biological processes, while the KH domain binds to RNA or ssDNA and is associated with transcriptional and translational regulation. In recent years, studies containing relevant information on ANKHD1 in cancer biology and its clinical relevance, as well as the increasing complexity of signaling networks in which this protein acts, have been reported.
    [Show full text]
  • Expanding the Genetic Heterogeneity of Intellectual Disability Shams Anazi*1, Sateesh Maddirevula*1, Yasmine T Asi2, Saud Alsahl
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Expanding the genetic heterogeneity of intellectual disability Shams Anazi*1, Sateesh Maddirevula*1, Yasmine T Asi2, Saud Alsahli1, Amal Alhashem3, Hanan E. Shamseldin1, Fatema AlZahrani1, Nisha Patel1, Niema Ibrahim1, Firdous M. Abdulwahab1, Mais Hashem1, Nadia Alhashmi4, Fathiya Al Murshedi4, Ahmad Alshaer12, Ahmed Rumayyan5,6, Saeed Al Tala7, Wesam Kurdi9, Abdulaziz Alsaman17, Ali Alasmari17, Mohammed M Saleh17, Hisham Alkuraya10, Mustafa A Salih11, Hesham Aldhalaan12, Tawfeg Ben-Omran13, Fatima Al Musafri13, Rehab Ali13, Jehan Suleiman14, Brahim Tabarki3, Ayman W El-Hattab15, Caleb Bupp18, Majid Alfadhel19, Nada Al-Tassan1,16, Dorota Monies1,16, Stefan Arold20, Mohamed Abouelhoda1,16, Tammaryn Lashley2, Eissa Faqeih17, Fowzan S Alkuraya1,3,16,21,18 *These authors have contributed equally 1Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 2Queen Square Brain Bank for Neurological Disorders, Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK. 3Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. 4Department of Genetics, College of Medicine, Sultan Qaboos University, Sultanate of Oman. 5King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. 6Neurology Division, Department of Pediatrics, King Abdulaziz Medical City, Riyadh, Saudi Arabia. 7Armed Forces Hospital Khamis Mushayt, Department of Pediatrics and Genetic Unit, Riyadh, Saudi Arabia. 9Department of Obstetrics and Gynecology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia 10Department of Ophthalmology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia. 11Division of Pediatric Neurology, Department of Pediatrics, King Khalid University Hospital and College of Medicine, King Saud University, Riyadh, Saudi Arabia.
    [Show full text]
  • A Genome-Wide Screen in Mice to Identify Cell-Extrinsic Regulators of Pulmonary Metastatic Colonisation
    FEATURED ARTICLE MUTANT SCREEN REPORT A Genome-Wide Screen in Mice To Identify Cell-Extrinsic Regulators of Pulmonary Metastatic Colonisation Louise van der Weyden,1 Agnieszka Swiatkowska, Vivek Iyer, Anneliese O. Speak, and David J. Adams Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, United Kingdom ORCID IDs: 0000-0002-0645-1879 (L.v.d.W.); 0000-0003-4890-4685 (A.O.S.); 0000-0001-9490-0306 (D.J.A.) ABSTRACT Metastatic colonization, whereby a disseminated tumor cell is able to survive and proliferate at a KEYWORDS secondary site, involves both tumor cell-intrinsic and -extrinsic factors. To identify tumor cell-extrinsic metastasis (microenvironmental) factors that regulate the ability of metastatic tumor cells to effectively colonize a metastatic tissue, we performed a genome-wide screen utilizing the experimental metastasis assay on mutant mice. colonisation Mutant and wildtype (control) mice were tail vein-dosed with murine metastatic melanoma B16-F10 cells and microenvironment 10 days later the number of pulmonary metastatic colonies were counted. Of the 1,300 genes/genetic B16-F10 locations (1,344 alleles) assessed in the screen 34 genes were determined to significantly regulate pulmonary lung metastatic colonization (15 increased and 19 decreased; P , 0.005 and genotype effect ,-55 or .+55). mutant While several of these genes have known roles in immune system regulation (Bach2, Cyba, Cybb, Cybc1, Id2, mouse Igh-6, Irf1, Irf7, Ncf1, Ncf2, Ncf4 and Pik3cg) most are involved in a disparate range of biological processes, ranging from ubiquitination (Herc1) to diphthamide synthesis (Dph6) to Rho GTPase-activation (Arhgap30 and Fgd4), with no previous reports of a role in the regulation of metastasis.
    [Show full text]
  • Number 3 March 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology
    Volume 1 - Number 1 May - September 1997 Volume 20 - Number 3 March 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematologyis a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. See also: http://documents.irevues.inist.fr/bitstream/handle/2042/56067/Scope.pdf Editorial correspondance Jean-Loup Huret, MD, PhD, Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France phone +33 5 49 44 45 46 [email protected] or [email protected] .
    [Show full text]
  • Large-Scale Analysis of Genome and Transcriptome Alterations in Multiple Tumors Unveils Novel Cancer-Relevant Splicing Networks
    Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks Endre Sebestyén1,*, Babita Singh1,*, Belén Miñana1,2, Amadís Pagès1, Francesca Mateo3, Miguel Angel Pujana3, Juan Valcárcel1,2,4, Eduardo Eyras1,4,5 1Universitat Pompeu Fabra, Dr. Aiguader 88, E08003 Barcelona, Spain 2Centre for Genomic Regulation, Dr. Aiguader 88, E08003 Barcelona, Spain 3Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), E08908 L’Hospitalet del Llobregat, Spain. 4Catalan Institution for Research and Advanced Studies, Passeig Lluís Companys 23, E08010 Barcelona, Spain *Equal contribution 5Correspondence to: [email protected] Keywords: alternative splicing, RNA binding proteins, splicing networks, cancer 1 Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting to be unveiled. We systematically analyzed mutation, copy number and gene expression patterns of 1348 RNA-binding protein (RBP) genes in 11 solid tumor types, together with alternative splicing changes in these tumors and the enrichment of binding motifs in the alternatively spliced sequences. Our comprehensive study reveals widespread alterations in the expression of RBP genes, as well as novel mutations and copy number variations in association with multiple alternative splicing changes in cancer drivers and oncogenic pathways. Remarkably, the altered splicing patterns in several tumor types recapitulate those of undifferentiated cells.
    [Show full text]
  • Molecular and Cytogenetic Analysis of the Spreading of X Inactivation in a Girl with Microcephaly, Mild Dysmorphic Features and T(X;5)(Q22.1;Q31.1)
    European Journal of Human Genetics (2008) 16, 897–905 & 2008 Nature Publishing Group All rights reserved 1018-4813/08 $30.00 www.nature.com/ejhg ARTICLE Molecular and cytogenetic analysis of the spreading of X inactivation in a girl with microcephaly, mild dysmorphic features and t(X;5)(q22.1;q31.1) Roberto Giorda*,1,7, M Clara Bonaglia2,7, Greta Milani1, Anna Baroncini3, Francesca Spada3, Silvana Beri1, Giorgia Menozzi4, Marianna Rusconi1 and Orsetta Zuffardi5,6 1Molecular Biology Laboratory, ‘E. Medea’ Scientific Institute, Bosisio Parini, Lecco, Italy; 2Cytogenetics Laboratory, ‘E. Medea’ Scientific Institute, Bosisio Parini, Lecco, Italy; 3UO Genetica Medica, AUSL Imola, Imola, Italy; 4Bioinformatic Laboratory, ‘E. Medea’ Scientific Institute, Bosisio Parini, Lecco, Italy; 5Biologia Generale e Genetica Medica, Universita` di Pavia, Pavia, Italy; 6IRCCS Policlinico San Matteo, Pavia, Italy X chromosome inactivation involves initiation, propagation, and maintenance of gene inactivation. Studies of replication pattern and timing in X;autosome translocations have suggested that X inactivation may spread to autosomal DNA. To examine this phenomenon at the molecular level, we have tested the transcriptional activity of a number of chromosome 5 loci in a female subject with microcephaly, mild dysmorphic features and 46,X,der(X)t(X;5)(q22.1;q31.1) karyotype. RT-PCR analysis of 20 transcribed sequences spanning 5q31.1-qter revealed that nine of them were not expressed in somatic cell hybrid clones carrying the translocated chromosome. However, eight genes were expressed and therefore escaped inactivation. This direct expression test demonstrates that spreading of inactivation from the X chromosome to the adjoining autosomal DNA was incomplete and ‘patchy’.
    [Show full text]
  • ANKHD1 (NM 017978) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC221886 ANKHD1 (NM_017978) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: ANKHD1 (NM_017978) Human Tagged ORF Clone Tag: Myc-DDK Symbol: ANKHD1 Synonyms: MASK; MASK1; PP2500; VBARP Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 ANKHD1 (NM_017978) Human Tagged ORF Clone – RC221886 ORF Nucleotide >RC221886 representing NM_017978 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGCTGACTGATAGCGGAGGCGGCGGCACCTCCTTTGAGGAGGACCTGGACTCTGTGGCTCCGCGATCCG CCCCAGCTGGGGCCTCGGAGCCGCCTCCGCCGGGAGGGGTCGGTCTGGGGATCCGCACCGTGAGGCTCTT TGGGGAGGCCGGGCCAGCGTCGGGAGTCGGCAGCAGCGGCGGCGGCGGCAGCGGCAGCGGTACGGGCGGA GGGGACGCGGCGCTGGATTTCAAGTTGGCGGCTGCCGTGCTGAGGACCGGGGGTGGAGGTGGTGCCTCTG GCAGTGACGAGGACGAAGTGTCCGAGGTTGAATCATTTATTTTGGACCAAGAAGATCTGGATAACCCAGT GCTTAAAACAACATCAGAGATATTCTTATCAAGTACTGCAGAAGGAGCAGACTTACGCACTGTGGATCCA GAGACACAGGCACGACTAGAAGCATTGCTAGAAGCAGCAGCTTTTGCAGATCCTGAGGTACTCCGGAGAC TGACATCCTCAGTTAGTTGTGCACTGGATGAAGCTGCTGCTGCACTGACACGGATGAAAGCAGAAAACAG CCACAATGCAGGACAAGTGGACACTCGCAGTCTAGCAGAAGCTTGTTCAGATGGGGATGTTAATGCTGTT
    [Show full text]
  • A Genome-Wide Screen in Mice to Identify Cell-Extrinsic Regulators of Pulmonary Metastatic Colonisation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.10.941401; this version posted February 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 A genome-wide screen in mice to identify cell-extrinsic regulators of pulmonary 2 metastatic colonisation 3 4 5 Louise van der Weyden1*, Agnieszka Swiatkowska1, Vivek Iyer1, Anneliese O. Speak1, David J. 6 Adams1 7 8 9 1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, 10 United Kingdom 11 12 13 *Corresponding author 14 Louise van der Weyden 15 Experimental Cancer Genetics 16 Wellcome Sanger Institute 17 Wellcome Genome Campus 18 Hinxton 19 Cambridge 20 CB10 1SA 21 United Kingdom 22 Tel: +44-1223-834-244 23 Email: [email protected] 24 25 26 KEYWORDS: metastasis, metastatic colonisation, microenvironment, B16-F10, lung, mutant, 27 mouse. 28 29 30 31 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.10.941401; this version posted February 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 32 ABSTRACT 33 34 Metastatic colonisation, whereby a disseminated tumour cell is able to survive and 35 proliferate at a secondary site, involves both tumour cell-intrinsic and -extrinsic factors.
    [Show full text]
  • Ankhd1 Enhances Polycystic Kidney Disease Development Via Promoting Proliferation and Fibrosis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.04.977017; this version posted March 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Ankhd1 enhances polycystic kidney disease development via promoting proliferation and fibrosis. Foteini Patera1✦, Guillaume M Hautbergue2, Patricia Wilson3, Paul C Evans1, Albert CM 1 1☆ Ong , Maria Fragiadaki . 1 Department of Infection Immunity and Cardiovascular disease, University of Sheffield Medical School, Sheffield, UK. 2Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK. 3 University College London Centre for Nephrology, University College London, London, United Kingdom. ☆Correspondence and requests for materials should be addressed to MF (email: [email protected]) Running title: ANKHD1 is a novel driver of ADPKD -------------------------------------------------------------------------------------------------------------------------------- ABSTRACT Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic kidney disorder resulting in 10% of patients with renal failure. The molecular events responsible for the relentless growth of cysts are not defined. Thus, identification of novel drivers of ADPKD may lead to new therapies. Ankyrin Repeat and Single KH domain-1 (ANKHD1) controls cancer cell proliferation, yet its role in ADPKD is unexplored. Here, we present the first data that identify ANKHD1 as a driver of proliferative growth in cellular and mouse models of ADPKD. Using the first Ankhd1-deficient mice, we demonstrate that Ankhd1 heterozygosity potently reduces cystic growth and fibrosis, in a genetically orthologous mouse model of ADPKD. We performed transcriptome-wide profiling of patient-derived ADPKD cells with and without ANKHD1 siRNA silencing, revealing a major role for ANKHD1 in the control of cell proliferation and matrix remodelling.
    [Show full text]
  • Phenotype Informatics
    Freie Universit¨atBerlin Department of Mathematics and Computer Science Phenotype informatics: Network approaches towards understanding the diseasome Sebastian Kohler¨ Submitted on: 12th September 2012 Dissertation zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) am Fachbereich Mathematik und Informatik der Freien Universitat¨ Berlin ii 1. Gutachter Prof. Dr. Martin Vingron 2. Gutachter: Prof. Dr. Peter N. Robinson 3. Gutachter: Christopher J. Mungall, Ph.D. Tag der Disputation: 16.05.2013 Preface This thesis presents research work on novel computational approaches to investigate and characterise the association between genes and pheno- typic abnormalities. It demonstrates methods for organisation, integra- tion, and mining of phenotype data in the field of genetics, with special application to human genetics. Here I will describe the parts of this the- sis that have been published in peer-reviewed journals. Often in modern science different people from different institutions contribute to research projects. The same is true for this thesis, and thus I will itemise who was responsible for specific sub-projects. In chapter 2, a new method for associating genes to phenotypes by means of protein-protein-interaction networks is described. I present a strategy to organise disease data and show how this can be used to link diseases to the corresponding genes. I show that global network distance measure in interaction networks of proteins is well suited for investigat- ing genotype-phenotype associations. This work has been published in 2008 in the American Journal of Human Genetics. My contribution here was to plan the project, implement the software, and finally test and evaluate the method on human genetics data; the implementation part was done in close collaboration with Sebastian Bauer.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Transposon Mutagenesis Identifies Genetic Drivers of Brafv600e Melanoma
    ARTICLES Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma Michael B Mann1,2, Michael A Black3, Devin J Jones1, Jerrold M Ward2,12, Christopher Chin Kuan Yew2,12, Justin Y Newberg1, Adam J Dupuy4, Alistair G Rust5,12, Marcus W Bosenberg6,7, Martin McMahon8,9, Cristin G Print10,11, Neal G Copeland1,2,13 & Nancy A Jenkins1,2,13 Although nearly half of human melanomas harbor oncogenic BRAFV600E mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in BrafV600E mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAFV600E melanoma and discover new genes with potential clinical importance in human melanoma. Substantial sun exposure and numerous genetic factors, including including BrafV600E, recapitulate the genetic and histological hallmarks skin type and family history, are the most important melanoma risk of human melanoma. In these models, increased MEK-ERK signaling factors. Familial melanoma, which accounts for <10% of cases, is asso- initiates clonal expansion of melanocytes, which is limited by oncogene- ciated with mutations in CDKN2A1, MITF2 and POT1 (refs.
    [Show full text]